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ABSTRACT: In this study, we examine the relationship between the physical structure and dissolution behavior of olanzapine (OLZ)
prepared via hot-melt extrusion in three polymers [polyvinylpyrrolidone (PVP) K30, polyvinylpyrrolidone-co-vinyl acetate (PVPVA) 6:4,
and Soluplus R© (SLP)]. In particular, we examine whether full amorphicity is necessary to achieve a favorable dissolution profile. Drug–
polymer miscibility was estimated using melting point depression and Hansen solubility parameters. Solid dispersions were characterized
using differential scanning calorimetry, X-ray powder diffraction, and scanning electron microscopy. All the polymers were found to be
miscible with OLZ in a decreasing order of PVP>PVPVA>SLP. At a lower extrusion temperature (160◦C), PVP generated fully amorphous
dispersions with OLZ, whereas the formulations with PVPVA and SLP contained 14%–16% crystalline OLZ. Increasing the extrusion
temperature to 180◦C allowed the preparation of fully amorphous systems with PVPVA and SLP. Despite these differences, the dissolution
rates of these preparations were comparable, with PVP showing a lower release rate despite being fully amorphous. These findings
suggested that, at least in the particular case of OLZ, the absence of crystalline material may not be critical to the dissolution performance.
We suggest alternative key factors determining dissolution, particularly the dissolution behavior of the polymers themselves. C© 2014 The
Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci
103:1214–1223, 2014
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INTRODUCTION
The oral bioavailability enhancement of poorly soluble active
pharmaceutical ingredients (APIs) continues to represent a sig-
nificant issue in drug development. One strategy to overcome
this obstacle is the development of amorphous solid dispersion
formulations using hydrophilic polymers. The term “solid dis-
persion” was described by Chiou and Riegelman1 as “the disper-
sion of one or more active ingredients in an inert carrier matrix
at solid state prepared by melting (fusion), solvent, or melting–
solvent method.” This definition is still applicable despite the
field having developed considerably to include a wider range
of manufacturing techniques [e.g., hot-melt extrusion (HME)]
and new concepts in structural characteristics, particularly in-
volving the recognition of complexities of molecular dispersion
of drugs in polymers.
The mechanisms underpinning the dissolution increase of
these formulations are still not yet clearly understood. Cur-
rently, there is a belief that the fundamental critical fac-
tor is the molecular dispersion of the drug in the polymer,
thereby representing the ultimate in particle size reduction
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and lattice energy negation. A number of papers have ad-
dressed these and associated issues such as wetting and re-
duction in agglomeration.2,3 In addition, earlier work in the
pre-HME solid dispersion field suggested that the drug disso-
lution may be controlled by the behavior of the carrier (so-called
“carrier controlled dissolution”), by implication suggesting that
the physical state of the drug may not be important in such
systems.4,5
The specific issue of whether full amorphization (in terms
of either molecular dispersion or amorphous phase generation)
is actually necessary to achieve fast and complete dissolution
has been addressed by previous authors. For example, Ver-
heyen et al.6 observed that the dissolution rate of diazepam
and temazepam could be enhanced when formulated into solid
dispersions with polyethylene glycol (PEG) 6000, although both
drugs remained in a highly crystalline state. The reason for this
behavior was attributed to the existence of a microenvironment
created by the polymer at the surface of the drug particles lead-
ing to a better wetting and solubilization properties.
In this study, we focused on the physical state properties of
the dispersions prepared with olanzapine (OLZ) and their in-
fluence on the dissolution performance. OLZ was formulated
with three hydrophilic polymers, polyvinylpyrrolidone (PVP)
K30, polyvinylpyrrolidone-co-vinyl acetate (PVPVA) 6:4, and
polyvinyl caprolactam-polyvinylacetate-PEG graft copolymer
(Soluplus R©, SLP) via HME. HME is a widely used technol-
ogy in which API and carrier are converted into a product
of uniform shape and density by the effect of heat and me-
chanical stress.7,8 HME represents a continuous solvent-free
manufacturing method and is relatively easy to scale-up, hence
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presenting a commercially viable approach to dosage form
development.
Olanzapine is an atypical antipsychotic agent used to
treat both negative and positive symptoms of schizophrenia,
acute mania with bipolar disorder, agitation, and psychotic
symptoms in dementia.9 According to Biopharmaceutical Clas-
sification System (BCS), OLZ is classified as a Class II drug
(low solubility, high permeability) with water solubility around
43 mg/L.10 OLZ has been suggested to crystallize in more than
50 different crystalline forms, including anhydrates, hydrates,
and solvates.11,12 In this study, anhydrous OLZ Form I, the
most stable form and currently used in pharmaceutical formu-
lations, was selected for study. In terms of the polymers used in
this work, numerous studies have been conducted on the solu-
bility enhancement of water-insoluble compounds, in particular
using PVP and its derivatives as carriers,13–16 with high solubi-
lization effects and the ability to establish hydrogen bonds with
APIs being well-recognized properties of these polymers.17,18
However, there are also issues associated with the use of these
materials, for example, PVP K30 has a high glass transition
temperature (Tg) and a relatively low degradation temperature
(Tdeg), which can represent an issue during processing via HME
because of the narrow temperature window of operation. More-
over, PVP is classified as an extremely hygroscopic substance,
which is attributed to the electronegative groups (C=O) in the
pyrrolidone structure being able to establish hydrogen bonding
with water.19 The copolymer PVPVA 6:4 has a 40% replacement
with lipophilic vinyl acetate functional groups and therefore it
is less hygroscopic than the homopolymer system.20 SLP on
the other hand is a synthetic polymer that combines both hy-
drophilic and hydrophobic components in its structure that fa-
cilitates increased solubilization of drugs and thus the prepara-
tion of fully amorphous solid dispersions. Moreover, the low Tg
(≈70◦C) compared with the PVP-based polymers permits easier
processing of thermolabile APIs, whereas its low hygroscopicity
has favorable stability implications. The chemical structures of
OLZ and each polymer are presented in Figure 1.
In this study, the freshly prepared HME systems were
characterized with particular reference to the miscibility and
Figure 1. Chemical structures of OLZ (a), SLP (b), PVP K30 (c), and
PVPVA 6:4 (d).
crystallinity of OLZ; the influence of drug physical state on
the dissolution performance was evaluated accordingly. At
first, we evaluated the optimal extrusion temperatures for the
OLZ–polymer systems based on the properties of each material
(i.e., Tg, Tm, and Tdeg). In addition, the thermodynamic solu-
bility/miscibility and interaction of OLZ in each polymer were
assessed using melting point depression (MPD)21,22 and solubil-
ity parameter23–25 approaches. The physicochemical properties
and the morphology of the extrudates were evaluated using dif-
ferential scanning calorimetry (DSC), X-ray powder diffraction
(XRPD), and scanning electron microscopy (SEM). In this man-
ner, it is intended that the association between the miscibility,
processing characteristics, physical structure, and dissolution
behavior of OLZ may be determined and compared for three
polymer systems, in turn leading to insights into the critical
factors determining performance.
EXPERIMENTAL
Materials
Olanzapine [molecular weight (Mw) = 312.43 g/mol, density
(D) = 1.30 g/cm3] was purchased from Myjoy Ltd. (India); PVP
K30 (Mw = 41.550 g/mol, D = 1.16 g/cm3), PVPVA 6:4 (Mw =
57.500 g/mol, D = 1.17 g/cm3), and SLP (Mw = 118.000 g/mol,
D = 1.20 g/cm3) were kindly donated by BASF Chemicals (Ger-
many). Methanol (analytical grade) was obtained from Sigma–
Aldrich (UK) . Phosphate buffer, pH 6.8 (Ph Eur), used in the
dissolution studies was prepared with potassium dihydrogen
orthophosphate (Fischer Scientific, UK) and sodium phosphate
dibasic (Sigma–Aldrich).
Methods
Preparation of HMEs
Hot-melt extrudates were prepared using a corotating twin
screw extruder Thermo Scientific HAAKE MiniLab II (Thermo
Scientific, UK). Formulations of OLZ with PVPVA and SLP
were prepared with ratios of 20:80 and 50:50 (w/w) and ex-
truded at 160◦C and 180◦C; the OLZ–PVP formulation was only
successfully prepared at 50:50 (w/w) and extruded at 160◦C.
Each system was prepared using a total weight of 5 g at a
speed of 100 rotations/min and mixed inside the barrel for
10 min. A round die with a diameter of 2 mm was attached
to the extruder.
Drug–Polymer Miscibility Prediction
Melting Point Depression. Olanzapine and polymers were
passed through a combination of sieves, and a fraction between
63 and 106 :m was used in all MPD experiments. Polymers
were dried over P2O5 for 48 h prior to usage. Physical mixtures
(PMs) with a drug ratio of 70%, 75%, 80%, 85%, 90%, and 100%
(w/w) were prepared at least in triplicate. The melting temper-
ature of OLZ both in the absence and presence of polymers was
measured using DSC at a scan rate of 10◦C/min in standard
pans.
Melting point depression results can be used to predict the
drug–polymer Flory–Huggins (FH) interaction parameter, P,
using Eq. (1),
(
1
Tmixm
− 1
Tpurem
)
= −R
Hfus
[
lnNdrug+
(
1− 1
m
)
Npolymer+PN2polymer
]
DOI 10.1002/jps.23894 Pina et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1214–1223, 2014
1216 RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology
(1)
where Tpurem and Hfus are the melting point and the enthalpy
of fusion of the drug, respectively; Tmixm is the melting point
of the drug when mixed with the polymer; N is the volume
fraction of the drug or polymer depending on the subscript and
m is the molar volume ratio of a polymer molecule to a drug
molecule.21,22
Gibbs Free Energy Change. The Flory–Huggins lattice theory
accounts for the entropy (Smix) and enthalpy (Hmix) of mixing
between large (polymers) and small molecules (APIs in the case
of solid dispersions).22,26 One way to express this relationship
is by considering the free energy of mixing, Gmix, at absolute
temperature (T), as expressed by Eq. (2),
Gmix = Hmix − TSmix (2)
The Flory–Huggins interaction parameter, P, which is re-
lated to the enthalpy and entropy of mixing, can be described
by Eq. (3),
Gmix
RT
= ndrug lnNdrug + npolymer lnNpolymer + ndrugNpolymerP (3)
where ndrug and npolymer are the number of moles of drug and
polymer, respectively. The first two terms on the right hand side
of the equation represent the entropy of mixing, whereas the
third term represents the enthalpy of mixing.
Hansen Solubility Parameter. The Hansen solubility parame-
ters, *, of drugs and polymers were calculated from their chem-
ical structures using the van Krevelen and Hoftyzer method
according to Eqs. (4) and (5).25 The total solubility parameter
(*t) was determined from the interactions between dispersion
forces (*d), polar interactions (*p), and hydrogen bonding (*h)
of the functional groups in the parent molecule divide by the
molar volume, V. The units of the solubility parameters are
MPa1/2.
*2 = *2p + *2p + *2h (4)
*=
√√√√√√(∑Fdi
V
)2⎛⎝
√∑
F2pi
V
⎞
⎠
2
+
(√∑
Ehi
V
)2
(5)
where Fdi, Fpi, and Ehi are the group contributions for different
component (dispersion forces, polar interactions, and hydrogen
bonding, respectively) of structural groups that are reported in
the literature at 25◦C.25
The drug–polymer interaction parameter, P, using the solu-
bility parameters difference between the drug and the polymer,
can be estimated as following,25
P = V0
RT
(*drug − *polymer)2 (6)
where V0 is the volume of the lattice site, R is the gas constant,
and T is the absolute temperature.
Crystallinity Quantification
The amount of crystalline OLZ present in the fresh extrudates
was estimated by constructing a calibration curve using the en-
thalpy of melting of OLZ in the presence of the polymer versus
the ratio of the drug in the mixture. This was performed in or-
der to account for changes in the melting behavior and enthalpy
caused by the presence of the polymer. PMs were prepared by
mixing OLZ and each polymer with a mortar and pestle in ra-
tios of 10:90, 20:80, 30:70, 50:50, 70:30, and 90:10 (w/w) and
analyzed in DSC. All the PMs were used with 63–106 :m par-
ticle size range.
Thermal Analysis
Standard DSC (Q2000; TA Instruments, New Castle, Delaware)
analysis was performed at a heating rate of 10◦C/min. Modu-
lated temperature DSC (Q2000; TA Instruments) analysis was
conducted using a heating rate of 2◦C/min, amplitude ±0.318◦C
and a period of 60 s. Scans were carried out within the temper-
ature range 0◦C–220◦C and TA standard crimped pans were
used in all experiments. Nitrogen purge gas was used with a
flow rate of 50 mL/min. Calibration was performed using n-
octadecane, benzoic acid, indium, and tin. For each sample,
measurements were repeated at least in triplicate.
Thermogravimetric analysis (TGA Q5000; TA Instruments)
was used to measure the degradation temperature (Tdeg) of the
raw materials and the water content of the fresh extrudates.
Analyses were conducted at 10◦C/min from room temperature
to 300◦C. Aluminum open pans were used.
X-Ray Powder Diffraction
X-ray powder diffraction (Thermo-ARL Xtra; Thermo Scientific)
spectra were collected from scans within the range 5.0◦–40.0◦
at 22 with a step size of 0.01◦ and time per step of 1 s. Ex-
trudates were premilled by mortar and pestle before the tests,
transferred into sample holders with a zero background and
placed onto a spinner stage. The X-ray source used was Cu K"1
with a voltage of 45 kV and current of 40 mA.
Scanning Electron Microscopy
Scanning electron microscopy (JSM 4900LV; JEOL Ltd., Japan)
was used to acquire microphotographs on the surface and cross-
section of the freshly prepared extrudates. To improve con-
ductivity prior to examination, samples were coated with gold
using a Polaron SC7640 sputter gold coater (Quorum Technolo-
gies, UK).
Dissolution Studies
The drug content of each formulation was determined by UV de-
tection (Lambda XLS UV/Vis; Perkin-Elmer) at 253 nm. Sam-
ples were dissolved in methanol and diluted with the same
solvent as appropriate.
Dissolution studies were carried out on a Copley CIS 8000
dissolution bath (Copley Scientific, UK). The USP paddle
method with a rotation speed of 50 rpm was employed and
900 mL of phosphate buffer pH 6.8 (Ph Eur) at the tempera-
ture of 37.0 ± 0.5◦C was used. Samples (pure OLZ and HME)
equivalent to 12 mg of OLZ (based on the drug loading of each
formulation) were used with a 63–106-:m sieve fraction. At
predetermined intervals, 10 mL of solution was withdrawn and
filtered through a 0.45-:m filter. Subsequently, the filtrate was
Pina et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1214–1223, 2014 DOI 10.1002/jps.23894
RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology 1217
y = −3.3445x + 0.9113
R² = 0.9837
y = −3.2606x + 0.929
R² = 0.9983
y = −2.5381x + 0.8932
R² = 0.9947
0.4
0.45
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1 0.11
[(
T m
ix
-1
)-
(T
m
-1
) 
x
ΔH
/-
R]
-[
1
-(
1
-m
) 
x
φ]
-l
n
φ
φ 2polymer
OLZ:PVP
OLZ:PVPVA
OLZ:SLP
Figure 2. Melting point depression results obtained for each OLZ–polymer system (PVP, PVPVA, and SLP). Slope of each curve included for
subsequent calculation of the Flory–Huggins interaction parameter (P).
analyzed spectrophotometrically at 253 nm. All the dissolution
experiments were performed under sink conditions.
To compare the dissolution performances between the dif-
ferent systems, a similarity factor (f2) was used. This is an
independent model that measures the similarity in percentage
between two profiles of dissolution27; f2 is a logarithmic recip-
rocal square root transformation of the square error, which can
be expressed by Eq. (7),
f 2 = 50 × log
⎧⎨
⎩
[
1 +
(
1
n
)
×
n∑
t=1
(Rt − Tt)2
]−0.5
× 100
⎫⎬
⎭ (7)
where n is the number of time points, Rt is the percentage of
drug release of a reference batch at the time t and Tt is the per-
centage of drug release of the comparison batch at time t. When
f2 is greater than 50 (i.e., 50–100), this indicates the sameness
or equivalence of the both compared profiles. Conversely, when
f2 is less than 50, then it is taken as both the profiles are dif-
ferent. In this study, the similarity factor was used to assess
differences in the dissolution profiles acquired up to a maxi-
mum of 45 min, depending on the system, as only one measure-
ment should be considered after both products have reached
85% dissolution.27
RESULTS
Estimation of Drug–Polymer Miscibility
We investigated the thermodynamic miscibility between OLZ
and each polymer by using two different approaches (described
earlier in the Experimental section): melting point depres-
sion and Hansen solubility parameter. The former method
describes the drug–polymer miscibility based on the Flory–
Huggins theory,28 which delineates entropy and enthalpy com-
ponents at a given temperature.29 Considering the lattice-based
models, the entropy of mixing is predicted to be relatively con-
stant (and favorable to mixing), being the balance between ad-
hesive and cohesive interactions that determines miscibility.
As a result, the mixing can be exothermic (Flory–Huggins in-
teraction parameter, P < 0), endothermic (P > 0), or athermal
(P = 0), which leads to different reduction magnitudes in the
melting point of the drug.21,22
The MDP results obtained for OLZ and each polymer system
are shown in Figure 2. In our study, all the interaction param-
eters, P, were found to be negative, indicating that all the three
polymers were miscible with OLZ and can be presented as fol-
lowing: −3.34 (R2 = 0.984) for OLZ–PVP, −3.26 (R2 = 0.998) for
OLZ–PVPVA, and finally −2.54 (R2 = 0.995) for the OLZ–SLP
system. On the basis of these results, the degree of miscibility
and interaction between OLZ and each polymer was suggested
to follow the decreasing rank order PVP>PVPVA>SLP.
Figure 3 shows the changes in the Gibbs free energy for
the three systems. For small values of the interaction parame-
ter, the free energy of mixing is negative and shows a concave
dependence on composition indicating miscibility. As expected
and according to Eq. (3), the Gmix is negative for all the OLZ–
polymer systems. However, lower values were seen for the OLZ–
PVP and OLZ–PVPVA systems when compared with OLZ–SLP,
thereby indicating greater miscibility for these two systems.
The second approach in analyzing OLZ–polymer system mis-
cibility was by using Hansen solubility parameters (*), which
were calculated based on van Krevelen and Hoftyzer group
contribution (Eq. (5)). The * for each component, difference be-
tween drug and each polymer (*), and interaction parame-
ter (P) are provided in Table 1. It is reported that compounds
with similar values of solubility parameter, nominally *< 7.0
MPa1/2, are more likely to be miscible, whereas if * > 10.0
MPa1/2 the compounds are most probably immiscible.30 From
the presented results, OLZ had a solubility parameter (25.68
MPa1/2) closer to PVP (26.28 MPa1/2), whereas PVPVA and SLP
had a slightly lower solubility parameter values, 24.37 and
DOI 10.1002/jps.23894 Pina et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1214–1223, 2014
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Figure 3. Free energy-composition phase diagrams of OLZ and each polymer system (PVP, PVPVA, and SLP).
Table 1. Calculated Solubility Parameters and Interaction
Parameters Using Hansen Group Contribution Theory for OLZ and
Each Polymer
Compound * (MPa)1/2 * (MPa)1/2 P
OLZ 25.68
PVP 26.28 0.60 0.03
PVPVA 24.37 1.31 0.16
SLP 23.07 2.61 0.62
23.07 MPa1/2, respectively. In the present case, the difference
between the solubility parameter of OLZ and each polymer
was lower than 7.0 MPa1/2, indicating good miscibility for all
systems.
The value of P, calculated based on Eq. (6), refers to the
square of the difference in solubility parameters that were cal-
culated from the values of group contributions at 25◦C. A closer
value of P to zero suggests greater interaction between the drug
and the polymer.25 According to the results in Table 1, the mis-
cibility between OLZ and each polymer is likely to follow the
same order as observed with MPD experiments (PVP>PVPVA>
SLP).
These two methods used here to predict drug–polymer misci-
bility have concomitant strengths and limitations, as has been
discussed extensively in the literature. In brief, the MPD ap-
proach is temperature and composition dependent, whereas the
calculation of solubility parameters allows the estimation of
the degree of miscibility based on the chemical structure of the
drug and polymer at room temperature.31,32 Moreover, MPD
methods may not be performed properly if the drug degrades
at the melting temperature, whereas the group contribution
method for the calculation of Hansen solubility is not applica-
ble for drug–polymer systems presenting strong intermolecular
interactions.33 In this work, the two approaches used to predict
the miscibility between OLZ and each polymer were in good
agreement, with PVP being identified by both as the polymer
presenting the greatest degree of miscibility with OLZ, followed
by PVPVA and finally SLP. The agreement between the two ap-
proaches lends weight to the applicability of the theoretical ap-
proaches used, although clearly experimental measurements,
as performed below, are ultimately the most reliable means of
testing miscibility.
Characterization of the Raw Materials
The optimal extrusion temperature has to be carefully deter-
mined based on the melting temperature (Tm) of the drug, the
Tg of the amorphous carrier, and the thermoplastic proper-
ties of the mixture.34 In particular, the temperature should
be higher than the glass transition temperature (Tg) of the
carrier in order to decrease the viscosity and promote an ad-
equate mixing with the drug and a suitable flow through the
extruder. Therefore, it is imperative that the thermal properties
of drug substances and excipients are well understood prior to
extrusion.
Table 2 shows the main thermal properties of OLZ and each
polymer. PVP has the highest Tg and the lowest degradation
temperature (Tdeg, measured by using TGA as the onset tem-
perature) when compared with PVPVA and SLP. Neither OLZ
nor the polymers appeared to degrade at the extrusion tem-
peratures used in this study (160◦C for all the three systems
and 180◦C for PVPVA and SLP as PVP degraded at this tem-
perature). Particular attention was paid to PVP because of the
smaller temperature interval between its Tg, Tdeg, and the pro-
cessing temperature. However, holding PVP isothermally in the
TGA at 160◦C for 30 min resulted in only a 0.8 ± 0.1% loss of
mass, suggesting that 160◦C might be a suitable temperature
for the extrusion of the OLZ–PVP formulation.
Table 2. Experimental Thermal Properties of OLZ and Polymers
Material Tm onset ± SD (◦C) Tg ± SD (◦C) Tdeg ± SD (◦C)
OLZ 193.6 ± 0.3 71.4 ± 0.4a 265.3 ± 4.0
PVP 161.6 ± 0.2 179.8 ± 1.6
PVPVA 105.6 ± 1.4 282.3 ± 1.0
SLP 72.9 ± 0.3 309.1 ± 1.3
aTg value obtained from heat-cool-heat cycle inside the DSC at 2◦C/min in
crimped pans.
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Figure 4. Differential scanning calorimetry curves of 50% drug-loaded formulations with SLP, PVPVA, and PVP (from top to bottom) extruded
at 160◦C and run at 10◦C/min in crimped pans.
Physical Characterization of HME Systems
Attempts to extrude PVP with a low drug loading of 20% were
unsuccessful. It is well known that the use of PVP in HME
formulations is limited because of its high Tg (≈160◦C) and
low Tdeg that is below 180◦C. Therefore, the incorporation of
small molecules of API allows the polymer segments to have
greater mobility because of plasticization effects and hence be
extruded at lower temperatures.35 Studies with ibuprofen and
ethyl cellulose showed that higher drug loadings of ibuprofen
not only eased the extrusion behavior of ethyl cellulose by de-
creasing its Tg but also improved the physical properties of the
prepared films.36,37 In the present study, the low drug loading
of 20% (w/w) did not elicit a suitable plasticization effect for
PVP and thus did not allow extrusion. However, when the drug
loading was increased to 50% (w/w), the extrusion process was
difficult but possible. As a result, the extrudates were prepared
in block-like shape with a rough appearance instead of thin
spaghetti-like strands as usually obtained in a smooth extru-
sion process. Despite these difficulties, this formulation (50%
OLZ–PVP) appeared to be completely amorphous with a single
Tg value and no evidence of recrystallization or melting of OLZ
was seen when analyzed in DSC, as shown in Figure 4.
The data in Figure 4 show an initial water loss peak reflect-
ing the approximately 1%–2% water content of these systems,
as measured by TGA, followed by a glass transition and, in some
cases, melting of the crystalline drug. Formulations of PVPVA
and SLP with 20% drug loading were easily extruded even at
160◦C as the Tg of these polymers is much lower (Tg (PVPVA) =
105◦C; Tg (SLP) = 70◦C). Therefore, their liquid-like state at that
temperature allowed an appropriate mixing with OLZ and a
consistent flow of the material through the barrel. However,
in contrast to the 50% OLZ–PVP system, the 50% drug-loaded
PVPVA and SLP formulations extruded at 160◦C were not fully
but only partially amorphous, which was confirmed by the melt-
ing of OLZ at ≈170◦C.
The quantification of crystalline OLZ in those extrudates was
calculated using calibration curves of the melting enthalpy of
OLZ when physically mixed with PVPVA or SLP in different ra-
tios, as shown in Figure 5. The percentage of drug crystallinity
was calculated to be 14.5 ± 1.6% and 16.5 ± 0.1% for the OLZ–
PVPVA and OLZ–SLP systems, respectively. These findings are
evidence of the high solubilization effect of PVP previously pre-
dicted by the MPD and Hansen methods when compared with
other polymers.
In terms of the PVPVA and SLP systems with a 50% drug
loading, when the temperature was increased to 180◦C, fully
amorphous solid dispersion systems were prepared without any
evidence of crystalline OLZ observed in DSC. Figure 6 shows
the measured Tg for all the formulated systems. The differ-
ence in the processing conditions (extrusion temperature) and
consequently the existence of crystalline OLZ in the final ex-
trudates did not have a great influence on the measured Tg
of the PVPVA and SLP systems. As expected, 50% OLZ–PVP
showed the highest Tg (≈108◦C), followed by the formulations
with PVPVA (≈90◦C) and finally SLP (≈74◦C).
The DSC findings outlined above were supported by the
XRPD studies that showed a considerable presence of crys-
talline OLZ (Fig. 7a) for the 50% drug-loaded PVPVA and SLP
extruded at 160◦C (Fig. 7b). Although the XRPD peaks in those
systems were relatively broad and with significant background
noise associated, it is still possible to confirm that the diffrac-
tion peaks did correspond to OLZ Form I. It was noted that the
diffraction peaks were broader than for the pure drug, possibly
indicating a reduction in crystal size. In contrast, no distinct
intensity peaks were observed in the diffractograms of the PVP
50% and in all 20% extruded formulations, confirming the for-
mation of fully amorphous solid dispersions.
Figure 8 depicts the scanning electron micrographs of the
surface and internal (cross-section surface) appearance of the
50% drug-loaded extrudates. The extrudates prepared with
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Figure 5. Calibration curves of the enthalpy of melting of OLZ in
the presence of PVPVA (top) or SLP (bottom) versus the ratio of crys-
talline OLZ in the PMs. Measurements were carried out at 10◦C/min in
crimped pans. Error bars represent the range for n = 3 measurements.
PVPVA and SLP at 160◦C showed a distribution of OLZ crys-
tals, either on the surface and cross-section, confirming the
incomplete melting of the drug during extrusion. In contrast,
the formulations extruded at 180◦C showed a complete smooth
surface without any evidence of crystalline OLZ. For the sys-
tem prepared with PVP, although no crystals were identified,
the surfaces of these extrudates were not completely smooth
as a consequence of the difficult extrusion process of this for-
mulation. For all the 20% drug-loaded formulations, no sign
of crystallinity was observed (data not shown). These observa-
tions were therefore in complete agreement with the results
obtained with DSC and XRPD.
Overall, following the physical characterization of the differ-
ent solid dispersion systems prepared with OLZ, we can mainly
divide them into two major groups:
1. Fully amorphous solid dispersions: 50% OLZ–PVP ex-
truded at 160◦C, 50% OLZ with PVPVA and SLP extruded
at 180◦C, and all the 20% drug-loaded formulations pre-
pared with PVPVA and SLP;
2. Partially amorphous solid dispersions: 50% OLZ with
PVPVA and SLP extruded at 160◦C. NB author comment
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Figure 6. Measured Tg values for all the freshly prepared formula-
tions using DSC (total heat flow) at 10◦C/min in crimped pans. Dashed
and dotted bars represent formulations extruded at 160◦C and 180◦C,
respectively.
0
1000
2000
3000
4000
5000
5 10 15 20 25 30 35 40
In
te
n
si
ty
2θ (degree)
a
5 10 15 20 25 30 35 40
In
te
n
si
ty
2θ (degree)
b
Figure 7. X-ray powder diffraction spectra of (a) pure OLZ and (b)
50% drug-loaded formulations from top to bottom: SLP, PVPVA, and
PVP extruded at 160◦C and SLP and PVPVA extruded at 180◦C.
It is noted that the greater miscibility of OLZ with PVP,
suggested by the MPD approach and solubility parameter
calculations, is supported by these findings. The question then
arises as to whether the variability in the degree of crystallinity
will have an influence on the associated drug release behavior.
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Figure 8. Photomicrographs of 1:1 fresh solid dispersion systems (surface and cross-section). Scale bar represents 100 :m.
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Figure 9. Dissolution profiles of pure OLZ and HME formulations with PVP, PVPVA, and SLP with 50% drug loading extruded at 160◦C and
180◦C (FAS, fully amorphous systems; PAS, partially amorphous systems). The legend on the right hand side follows the same order as the curves
in the plot (top to bottom).
Dissolution Studies
The drug content of all formulations was at 95.6%–104.0%
of the theoretical values. Figures 9 and 10 show the dissolu-
tion curves of pure OLZ and freshly prepared HME formula-
tions at 50% and 20% drug loading, respectively. A significant
enhancement in the dissolution rate was observed for all solid
dispersion systems prepared by HME compared with the pure
crystalline OLZ. More specifically, in the case of the 50% drug-
loaded formulations, the T50 values were approximately 3 min
for the dispersions with PVPVA and SLP (either extruded
at 160◦C or 180◦C) compared with 10 min for the OLZ–PVP
and finally 30 min for the drug alone. The formulations con-
taining 20% OLZ extruded with PVPVA and SLP showed an
even faster dissolution rate with T50 values between 1 and
2 min at both processing temperatures. It was interesting to
observe in Figure 9 that with a constant drug loading (50%)
and processing temperature (160◦C), the decreasing order of
drug release rate from different polymer-based systems was
PVPVA (partially amorphous) > SLP (partially amorphous) >
PVP (fully amorphous). This indicates that drug release may
not always be faster from a fully amorphous state than a par-
tially amorphous structure with crystal domains.
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Figure 10. Dissolution profiles of 20% drug-loaded HME formula-
tions with PVPVA and SLP extruded at 160◦C and 180◦C (all systems
were characterized as fully amorphous systems). The legend on the
right hand side follows the same order as the curves in the plot (top to
bottom).
In addition, PVPVA and SLP systems extruded at the two
different temperatures produced very similar dissolution pro-
files. More specifically, the similarity factor, f2, for the 50%
OLZ–PVPVA systems was calculated to be 65.6, whereas for
the case of OLZ–SLP f2 had a borderline value of 50.5. Never-
theless, in both cases, f2 was greater than 50 indicating that
the release profile of the drug from the partially (extrusion at
160◦C) and fully (extrusion at 180◦C) amorphous solid disper-
sions was comparable in this specific case.
The dissolution curves of the 20% drug-loaded formulations
extruded at the different temperatures were found to be su-
perimposable for each polymer system (Fig. 10). Furthermore,
the release profile was controlled by the type of polymer with
the formulations prepared with SLP showing a slower release
rate when compared with PVPVA. However, at this drug load-
ing, fully amorphous solid solutions were obtained with both
processing temperatures and therefore these results are not
surprising.
DISCUSSION
Overall, the predicted miscibility and interaction between OLZ
and each polymer calculated based on both MPD and Hansen
solubility parameters agreed with the experimental results in
that at the same extrusion temperature (160◦C) and drug load-
ing (50%); PVP was found to have the greatest miscibility with
OLZ leading to the molecular dispersion of OLZ. In contrast,
the formulations prepared with PVPVA and SLP, under the
same conditions, crystalline OLZ was detected via DSC, XRPD,
and SEM observations. At a higher extrusion temperature, both
formulations with PVPVA and SLP were characterized as one-
phase systems with a single Tg value observed in DSC. This
therefore demonstrates the complex interplay between misci-
bility and processing but also demonstrates that there is a role
for MPD and solubility parameter predictions in anticipating
experimental findings.
In terms of the dissolution performance, the general assump-
tion that a higher dissolution rate is obtained when the drug
is completely converted to an amorphous form is not consistent
with our findings. In this specific case, it was noted that at 50%
loading and 160◦C processing, PVP showed the slowest release
despite being the only fully amorphous system. Clearly, there-
fore, the nature of the polymer is an important determinant
of dissolution as well as the degree of crystallinity. However,
what is particularly interesting is that the two 50% dispersions
in PVPVA and SLP at 160◦C and 180◦C also showed no differ-
ences, despite these being the same polymers but with differing
degrees of drug crystallinity.
Earlier work in the solid dispersion literature4,5 has sug-
gested that dissolution rates of some or many binary systems
may be determined by the dissolution of the carrier polymer
and not the drug at all. More specifically, it has been suggested
that the polymer may form a concentrated layer adjacent to the
solid surface into which the drug may dissolve rapidly; hence,
it is the dissolution of the polymer-rich layer that determines
drug release and not the actual dissolution of the drug itself.
The results presented here are consistent with this hypothesis;
hence, we suggest that this is an area that requires further
study, as at present the emphasis on storage stability has been
focused on the physical characteristics of the drug and the ten-
dency to phase separation. We suggest that it may in fact be
the characteristics of the polymer that are changing and the
drug structure may, in some cases at least, be incidental and
irrelevant to performance.
CONCLUSIONS
In this study, we have shown that the differences in the phys-
ical structure of the extruded systems prepared with OLZ are
a consequence of the physicochemical properties of the choice
of polymer, the drug loading, and the processing temperature.
We have demonstrated that MPD and solubility parameter ap-
proaches may play a role in predicting miscibility and that there
is an interplay between processability and the tendency to form
molecular dispersions, with low and high temperatures result-
ing in poor processing or degradation, respectively, whereas
higher temperatures favor molecular dispersion. It was inter-
esting to note that no clear relationship was found between
dissolution and drug crystallinity or indeed with processing
temperature, with the release rates being much more depen-
dent on the choice of polymer. We suggest that, in this case at
least, it may be the behavior of the polymer that determines
dissolution performance rather than the physical state of the
drug.
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